Key result
Liraglutide treatment for 12 weeks resulted in a significantly greater reduction in total weight loss compared to control (11.6% vs 4.9%, MD 6.6%) in patients remaining obese 6 months after metabolic surgery.
Why the study?
The safety and efficacy of liraglutide as a weight loss intervention in individuals who remain obese within 1 year after metabolic surgery remain unclear.
Does liraglutide 1.8 mg daily improve total weight loss in patients remaining obese 6 months after metabolic surgery?
Population
61 patients remaining obese (BMI ≥ 28.0 kg/m2) 6 months after metabolic surgery
Comparison
Liraglutide 1.8 mg for 12 weeks vs control
Design
Retrospective cohort study
Follow-up
24 weeks
Authors
Loading...
Liraglutide was associated with greater post-metabolic surgery weight loss; hypothesis-generating for adjunctive use pending randomized confirmation.
Cohort (n=61)
No
Does liraglutide 1.8 mg daily improve total weight loss in patients remaining obese 6 months after metabolic surgery?
Mean Difference: 6.6 (95% CI 3.7–9.6)
Absolute Event Rate: 11.6% vs 4.9%
p-value: p=<0.01
In patients remaining obese 6 months after metabolic surgery, 12 weeks of adjuvant liraglutide significantly increased weight loss and improved metabolic comorbidities compared to lifestyle intervention alone.
Shen et al. (2024) conducted a cohort in Persistent obesity after metabolic surgery (n=61). Liraglutide vs. Diet-exercise program was evaluated on Change in total weight loss (%TWL) after 24 weeks (MD 6.6%, 95% CI 3.7-9.6, p=<0.01). Liraglutide treatment for 12 weeks resulted in a significantly greater reduction in total weight loss compared to control (11.6% vs 4.9%, MD 6.6%) in patients remaining obese 6 months after metabolic surgery.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: